<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">russjcardiol</journal-id><journal-title-group><journal-title xml:lang="ru">Российский кардиологический журнал</journal-title><trans-title-group xml:lang="en"><trans-title>Russian Journal of Cardiology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1560-4071</issn><issn pub-type="epub">2618-7620</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15829/1560-4071-2018-1-72-77</article-id><article-id custom-type="elpub" pub-id-type="custom">russjcardiol-2610</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОБЗОРЫ ЛИТЕРАТУРЫ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>REVIEW</subject></subj-group></article-categories><title-group><article-title>ИММУННЫЙ ОТВЕТ ПРИ ДЕКОМПЕНСАЦИИ ИШЕМИЧЕСКОЙ ХРОНИЧЕСКОЙ СЕРДЕЧНОЙ  НЕДОСТАТОЧНОСТИ</article-title><trans-title-group xml:lang="en"><trans-title>IMMUNE RESPONSE IN DECOMPENSATED CHRONIC HEART FAILURE OF ISCHEMIC ORIGIN</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9409-9085</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кручинкина</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Kruchinkina</surname><given-names>E. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кручинкина Екатерина Владимировна — аспирант отделения неотложной кардиологии</p></bio><bio xml:lang="en"><p>Ekaterina V. Kruchinkina - postgraduate student of the Cardiac Emergency Department; Cardiologist of the Cardiac Emergency Department</p></bio><email xlink:type="simple">katy990@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4358-7329</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Рябов</surname><given-names>В. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Ryabov</surname><given-names>V. V.</given-names></name></name-alternatives><bio xml:lang="ru"/><bio xml:lang="en"/><email xlink:type="simple">rvvt@cardio-tomsk.ru</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Научно-исследовательский институт кардиологии, Томский национальный исследовательский медицинский центр Российской академии наук</institution><country>Россия</country></aff><aff xml:lang="en"><institution>SRI of Cardiology, Tomsk National Research Medical Center of RAS</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Научно-исследовательский институт кардиологии, Томский национальный исследовательский медицинский центр Российской академии наук; ФГАОУ ВО Национальный исследовательский Томский государственный университет; ГБОУ ВПО Сибирский государственный медицинский университет Министерства Здравоохранения</institution><country>Россия</country></aff><aff xml:lang="en"><institution>SRI of Cardiology, Tomsk National Research Medical Center of RAS; Tomsk National Research State University; Siberian State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2018</year></pub-date><pub-date pub-type="epub"><day>08</day><month>03</month><year>2018</year></pub-date><volume>0</volume><issue>1</issue><fpage>72</fpage><lpage>77</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Кручинкина Е.В., Рябов В.В., 2018</copyright-statement><copyright-year>2018</copyright-year><copyright-holder xml:lang="ru">Кручинкина Е.В., Рябов В.В.</copyright-holder><copyright-holder xml:lang="en">Kruchinkina E.V., Ryabov V.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://russjcardiol.elpub.ru/jour/article/view/2610">https://russjcardiol.elpub.ru/jour/article/view/2610</self-uri><abstract><p>В настоящее время определена значимость роли воспаления в патофизиологии хронической сердечной недостаточности (ХСН). Достоверно известно, что повышенный уровень циркулирующих провоспалительных цитокинов у пациентов с ишемической ХСН коррелирует с тяжестью и прогнозом заболевания. Моноциты играют ключевую роль в воспалительном каскаде и являются основным источником как про- и противовоспалительных цитокинов. Дисбаланс физиологического воспаления при повреждении и восстановлении миокарда может привести к формированию патологического хронического воспаления. В этой статье обсуждается роль моноцитов и воспаления при ХСН и ее декомпенсации, а также представлено описание видов цитокинов и их участия в воспалении. Кроме того, представлен анализ результатов исследований лекарственных препаратов, направленных на модуляцию иммунной реакции при ХСН.</p></abstract><trans-abstract xml:lang="en"><p>Recently, a significance has been established, for the role of inflammation in the pathology of chronic heart failure (CHF). It is well known that raised level of circulating pro-inflammatory cytokines in ischemic CHF patients correlate with the severity and prognosis of the disease. Monocytes play key role in an inflammatory cascade and are the main source of pro-, as contra-inflammatory cytokines. Disbalance of physiological inflammation in alteration and healing of the myocardium might lead to formation of pathological chronic inflammation. In the article, the role of monocytes discussed, and of inflammation, in CHF and its decompensation. The kinds of cytokines observed with their role in inflammation. Also, the analysis presented, of the drugs used for modulation of immune response in CHF.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>острая декомпенсация хронической сердечной недостаточности</kwd><kwd>макрофаги</kwd><kwd>цитокины</kwd><kwd>врожденный иммунитет</kwd><kwd>адаптивный иммунитет</kwd></kwd-group><kwd-group xml:lang="en"><kwd>acute decompensation of chronic heart failure</kwd><kwd>macrophages</kwd><kwd>cytokines</kwd><kwd>innate immunity</kwd><kwd>adaptive immunity</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Searle J, Frick J, Möckel M. Acute heart failure facts and numbers: acute heart failure populations. ESC Heart Failure. 2016; 3: 65-70. DOI: 10.1002/ehf2.12092.</mixed-citation><mixed-citation xml:lang="en">Searle J, Frick J, Möckel M. Acute heart failure facts and numbers: acute heart failure populations. ESC Heart Failure. 2016; 3: 65-70. DOI: 10.1002/ehf2.12092.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Grilo GA, Shaver PR, Castro Bra´s LE. Mechanisms of cardioprotection via modulation of the immune response. Current Opinion in Pharmacology 2017, 33: 6-11. DOI: 10.1016/j.coph.2017.03.002.</mixed-citation><mixed-citation xml:lang="en">Grilo GA, Shaver PR, Castro Bra´s LE. Mechanisms of cardioprotection via modulation of the immune response. Current Opinion in Pharmacology 2017, 33: 6-11. DOI: 10.1016/j.coph.2017.03.002.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Kawaguchi M, Takahashi M, Hata T, et al. Inflammasome activation of cardiac fibroblasts is essential for myocardial ischemia/reperfusion injury. Circulation 2011; 123: 594-604. DOI: 10.1161/CIRCULATIONAHA.110.982777.</mixed-citation><mixed-citation xml:lang="en">Kawaguchi M, Takahashi M, Hata T, et al. Inflammasome activation of cardiac fibroblasts is essential for myocardial ischemia/reperfusion injury. Circulation 2011; 123: 594-604. DOI: 10.1161/CIRCULATIONAHA.110.982777.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Dick SA, Epelman S. Chronic Heart Failure and Inflammation What Do We Really Know? Circulation Research. 2016; 119: 159-76. DOI: 10.1161/CIRCRESAHA.116.308030.</mixed-citation><mixed-citation xml:lang="en">Dick SA, Epelman S. Chronic Heart Failure and Inflammation What Do We Really Know? Circulation Research. 2016; 119: 159-76. DOI: 10.1161/CIRCRESAHA.116.308030.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Yang Y, Lv J, Jiang S, et al. The emerging role of Toll-like receptor 4 in myocardial inflammation. Cell Death Dis 2016, 7: e2234.</mixed-citation><mixed-citation xml:lang="en">Yang Y, Lv J, Jiang S, et al. The emerging role of Toll-like receptor 4 in myocardial inflammation. Cell Death Dis 2016, 7: e2234.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Sharma S, Garg I, Ashraf MZ. TLR signalling and association of TLR polymorphism with cardiovascular diseases. Vasc Pharmacol 2016, 87: 30-7.</mixed-citation><mixed-citation xml:lang="en">Sharma S, Garg I, Ashraf MZ. TLR signalling and association of TLR polymorphism with cardiovascular diseases. Vasc Pharmacol 2016, 87: 30-7.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Xu J, Sachdev U. The Toll of vascular insufficiency: implications for the management of peripheral arterial disease. J Immunol Res 2016, 2016: 8249015.</mixed-citation><mixed-citation xml:lang="en">Xu J, Sachdev U. The Toll of vascular insufficiency: implications for the management of peripheral arterial disease. J Immunol Res 2016, 2016: 8249015.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Fujiu K, Wang J, Nagai R. Cardioprotective function of cardiac macrophages. Cardiovasc Res 2014, 102: 232-9.</mixed-citation><mixed-citation xml:lang="en">Fujiu K, Wang J, Nagai R. Cardioprotective function of cardiac macrophages. Cardiovasc Res 2014, 102: 232-9.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Gombozhapova A, Rogovskaya Y, Shurupov V, et al. Macrophage activation and polarization in post-infarction cardiac remodeling. J Biomed Sci. 2017; 24 (1): 13. DOI: 10.1186/s12929-017-0322-3.</mixed-citation><mixed-citation xml:lang="en">Gombozhapova A, Rogovskaya Y, Shurupov V, et al. Macrophage activation and polarization in post-infarction cardiac remodeling. J Biomed Sci. 2017; 24 (1): 13. DOI: 10.1186/s12929-017-0322-3.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Jeong HY, Kang WS, Hong MH, et al. 5-Azacytidine modulates interferon regulatory factor 1 in macrophages to exert a cardioprotective effect. Sci Rep 2015, 5: 15768.</mixed-citation><mixed-citation xml:lang="en">Jeong HY, Kang WS, Hong MH, et al. 5-Azacytidine modulates interferon regulatory factor 1 in macrophages to exert a cardioprotective effect. Sci Rep 2015, 5: 15768.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Wan E, Yeap XY, Dehn S, et al. Enhanced efferocytosis of apoptotic cardiomyocytes through myeloid-epithelial-reproductive tyrosine kinase links acute inflammation resolution to cardiac repair after infarction. Circ Res 2013, 113: 1004-12.</mixed-citation><mixed-citation xml:lang="en">Wan E, Yeap XY, Dehn S, et al. Enhanced efferocytosis of apoptotic cardiomyocytes through myeloid-epithelial-reproductive tyrosine kinase links acute inflammation resolution to cardiac repair after infarction. Circ Res 2013, 113: 1004-12.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Frangogiannis NG: Emerging roles for macrophages in cardiac injury: cytoprotection, repair, and regeneration. J Clin Invest 2015, 125: 2927-30.</mixed-citation><mixed-citation xml:lang="en">Frangogiannis NG: Emerging roles for macrophages in cardiac injury: cytoprotection, repair, and regeneration. J Clin Invest 2015, 125: 2927-30.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Frantz S, Hofmann U, Fraccarollo D, et al. Monocytes/macrophages prevent healing defects and left ventricular thrombus formation after myocardial infarction. FASEB J 2013, 27: 871-81.</mixed-citation><mixed-citation xml:lang="en">Frantz S, Hofmann U, Fraccarollo D, et al. Monocytes/macrophages prevent healing defects and left ventricular thrombus formation after myocardial infarction. FASEB J 2013, 27: 871-81.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Ryabov VV, Gombozhapova AE, Rogovskaya Yu.V., et al. Functional plasticity of monocytes/ macrophages in the processes of recovery and regeneration post-infarction remodeling of the heart. Immunology. 2016; 37 (6): 305-12. (In Russ.) Рябов В. В., Гомбожапова А. Э., Роговская Ю. В., и др. Функциональная пластичность моноцитов/макрофагов в процессах восстановительной регенерации и постинфарктного ремоделирования сердца. Иммунология. 2016; 37 (6): 305-12.</mixed-citation><mixed-citation xml:lang="en">Ryabov VV, Gombozhapova AE, Rogovskaya Yu.V., et al. Functional plasticity of monocytes/ macrophages in the processes of recovery and regeneration post-infarction remodeling of the heart. Immunology. 2016; 37 (6): 305-12. (In Russ.) Рябов В. В., Гомбожапова А. Э., Роговская Ю. В., и др. Функциональная пластичность моноцитов/макрофагов в процессах восстановительной регенерации и постинфарктного ремоделирования сердца. Иммунология. 2016; 37 (6): 305-12.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Goodchild TT, Robinson KA, Pang W, et al. Bone marrow-derived B cells preserve ventricular function after acute myocardial infarction. JACC Cardiovasc Interv 2009, 2: 1005-16.</mixed-citation><mixed-citation xml:lang="en">Goodchild TT, Robinson KA, Pang W, et al. Bone marrow-derived B cells preserve ventricular function after acute myocardial infarction. JACC Cardiovasc Interv 2009, 2: 1005-16.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang Y, Bauersachs J, Langer HF. Immune mechanisms in heart failure. Eur J Heart Fail. 2017; 19 (11): 1379-89. DOI: 10.1002/ejhf.942.</mixed-citation><mixed-citation xml:lang="en">Zhang Y, Bauersachs J, Langer HF. Immune mechanisms in heart failure. Eur J Heart Fail. 2017; 19 (11): 1379-89. DOI: 10.1002/ejhf.942.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Pistulli R, König S, Drobnik S, et al. Decrease in dendritic cells in endomyocardial biopsies of human dilated cardiomyopathy. Eur J Heart Fail. 2013; 15: 974-85.</mixed-citation><mixed-citation xml:lang="en">Pistulli R, König S, Drobnik S, et al. Decrease in dendritic cells in endomyocardial biopsies of human dilated cardiomyopathy. Eur J Heart Fail. 2013; 15: 974-85.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Coder B, Wang W, Wang L, et al. Friend or foe: the dichotomous impact of T cells on neurode/re-generation during aging. Oncotarget 2017, 8: 7116-37.</mixed-citation><mixed-citation xml:lang="en">Coder B, Wang W, Wang L, et al. Friend or foe: the dichotomous impact of T cells on neurode/re-generation during aging. Oncotarget 2017, 8: 7116-37.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Yu HT, Park S, Shin EC, Lee WW: T cell senescence and cardiovascular diseases. Clin Exp Med 2016, 16: 257-63.</mixed-citation><mixed-citation xml:lang="en">Yu HT, Park S, Shin EC, Lee WW: T cell senescence and cardiovascular diseases. Clin Exp Med 2016, 16: 257-63.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Moro-García MA, Echeverría A, Galán-Artímez MC, et al. Immunosenescence and inflammation characterize chronic heart failure patients with more advanced disease. International Journal of Cardiology. 2014: 1-10. DOI: 10.1016/j.ijcard.2014.04.128.</mixed-citation><mixed-citation xml:lang="en">Moro-García MA, Echeverría A, Galán-Artímez MC, et al. Immunosenescence and inflammation characterize chronic heart failure patients with more advanced disease. International Journal of Cardiology. 2014: 1-10. DOI: 10.1016/j.ijcard.2014.04.128.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016; 18: 891-975.</mixed-citation><mixed-citation xml:lang="en">Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016; 18: 891-975.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Levine B, Kalman J, Mayer L, et al. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med. 1990; 323 (4): 236-41.</mixed-citation><mixed-citation xml:lang="en">Levine B, Kalman J, Mayer L, et al. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med. 1990; 323 (4): 236-41.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Awad AE, Kandalam V, Chakrabarti S, et al. Tumor necrosis factor induces matrix metalloproteinases in cardiomyocytes and cardiofibroblasts differentially via superoxide production in a PI3Kgamma-dependent manner. Am J Physiol Cell Physiol. 2010; 298 (3): C679-92.</mixed-citation><mixed-citation xml:lang="en">Awad AE, Kandalam V, Chakrabarti S, et al. Tumor necrosis factor induces matrix metalloproteinases in cardiomyocytes and cardiofibroblasts differentially via superoxide production in a PI3Kgamma-dependent manner. Am J Physiol Cell Physiol. 2010; 298 (3): C679-92.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Amin HZ, Amin LZ, Wijaya IP. Galectin-3: a novel biomarker for the prognosis of heart failure. Clujul Med. 2017; 90 (2): 129-32. DOI: 10.15386/cjmed-751.</mixed-citation><mixed-citation xml:lang="en">Amin HZ, Amin LZ, Wijaya IP. Galectin-3: a novel biomarker for the prognosis of heart failure. Clujul Med. 2017; 90 (2): 129-32. DOI: 10.15386/cjmed-751.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Sager HB, Heidt T, Hulsmans M, et al. Targeting interleukin-1β reduces leukocyte production after acute myocardial infarction. Circulation 2015; 132: 1880-90.</mixed-citation><mixed-citation xml:lang="en">Sager HB, Heidt T, Hulsmans M, et al. Targeting interleukin-1β reduces leukocyte production after acute myocardial infarction. Circulation 2015; 132: 1880-90.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Braunwald E. Heart Failure. JACC: Heart Failure. 2013; 1 (1): 1-20. DOI: 10.1016/j.jchf.2012.10.002.</mixed-citation><mixed-citation xml:lang="en">Braunwald E. Heart Failure. JACC: Heart Failure. 2013; 1 (1): 1-20. DOI: 10.1016/j.jchf.2012.10.002.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Ptaszynska-Kopczynska K, Szpakowicz A, Marcinkiewicz-Siemion M, et al. Interleukin-6 signaling in patients with chronic heart failure treated with cardiac resynchronization therapy. Arch Med Sci. 2017 Aug; 13 (5): 1069-77. DOI: 10.5114/aoms.2016.58635.</mixed-citation><mixed-citation xml:lang="en">Ptaszynska-Kopczynska K, Szpakowicz A, Marcinkiewicz-Siemion M, et al. Interleukin-6 signaling in patients with chronic heart failure treated with cardiac resynchronization therapy. Arch Med Sci. 2017 Aug; 13 (5): 1069-77. DOI: 10.5114/aoms.2016.58635.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Ueland T, Gullestad L, Nymo SH, et al. Inflammatory cytokines as biomarkers in heart failure. Clin Chim Acta. 2015; 443: 71-7. DOI: 10.1016/j.cca.2014.09.001.</mixed-citation><mixed-citation xml:lang="en">Ueland T, Gullestad L, Nymo SH, et al. Inflammatory cytokines as biomarkers in heart failure. Clin Chim Acta. 2015; 443: 71-7. DOI: 10.1016/j.cca.2014.09.001.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Kakkar R, Lee RT. The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nat Rev Drug Discov 2008; 7: 827-40. DOI: 10.1038/nrd2660.</mixed-citation><mixed-citation xml:lang="en">Kakkar R, Lee RT. The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nat Rev Drug Discov 2008; 7: 827-40. DOI: 10.1038/nrd2660.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Miller AM, Liew FY. The IL-33/ST2 pathway a new therapeutic target in cardiovascular disease. Pharmacol Ther. 2011 Aug; 131 (2): 179-86. DOI: 10.1016/j.pharmthera.2011.02.005.</mixed-citation><mixed-citation xml:lang="en">Miller AM, Liew FY. The IL-33/ST2 pathway a new therapeutic target in cardiovascular disease. Pharmacol Ther. 2011 Aug; 131 (2): 179-86. DOI: 10.1016/j.pharmthera.2011.02.005.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Tao R, Fan Q, Zhang H, et al. Prognostic Significance of Interleukin-34 (IL-34) in Patients with Chronic Heart Failure with or Without Renal Insufficiency. J Am Heart Assoc. 2017 Apr 1; 6 (4): e004911. DOI: 10.1161/JAHA.116.004911.</mixed-citation><mixed-citation xml:lang="en">Tao R, Fan Q, Zhang H, et al. Prognostic Significance of Interleukin-34 (IL-34) in Patients with Chronic Heart Failure with or Without Renal Insufficiency. J Am Heart Assoc. 2017 Apr 1; 6 (4): e004911. DOI: 10.1161/JAHA.116.004911.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Bansal SS, Ismahil MA, Goel M, et al. Activated T Lymphocytes are Essential Drivers of Pathological Remodeling in Ischemic Heart Failure.Circulation: Heart Failure. 2017; 10: e003688, originally published February 27, 2017. DOI: 10.1161/ CIRCHEARTFAILURE.116.003688.</mixed-citation><mixed-citation xml:lang="en">Bansal SS, Ismahil MA, Goel M, et al. Activated T Lymphocytes are Essential Drivers of Pathological Remodeling in Ischemic Heart Failure.Circulation: Heart Failure. 2017; 10: e003688, originally published February 27, 2017. DOI: 10.1161/ CIRCHEARTFAILURE.116.003688.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Verma SK, Krishnamurthy P, Barefield D, et al. Interleukin-10 treatment attenuates pressure overload-induced hypertrophic remodeling and improves heart function via signal transducers and activators of transcription 3-dependent inhibition of nuclear factor-κB. Circulation 2012; 126: 418-29. DOI: 10.1161/CIRCULATIONAHA.112.112185.</mixed-citation><mixed-citation xml:lang="en">Verma SK, Krishnamurthy P, Barefield D, et al. Interleukin-10 treatment attenuates pressure overload-induced hypertrophic remodeling and improves heart function via signal transducers and activators of transcription 3-dependent inhibition of nuclear factor-κB. Circulation 2012; 126: 418-29. DOI: 10.1161/CIRCULATIONAHA.112.112185.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Mann DL. Innate immunity and the failing heart: the cytokine hypothesis revisited. Circ Res. 2015; 116: 1254-68. DOI: 10.1161/CIRCRESAHA.116.302317.</mixed-citation><mixed-citation xml:lang="en">Mann DL. Innate immunity and the failing heart: the cytokine hypothesis revisited. Circ Res. 2015; 116: 1254-68. DOI: 10.1161/CIRCRESAHA.116.302317.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Chung ES, Packer M, Lo KH, et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003; 107 (25): 3133-40. DOI: 10.1161/01.CIR.0000077913.60364.D2.</mixed-citation><mixed-citation xml:lang="en">Chung ES, Packer M, Lo KH, et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003; 107 (25): 3133-40. DOI: 10.1161/01.CIR.0000077913.60364.D2.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Mann DL, McMurray J, Packer M, et al. Targeted Anticytokine Therapy in Patients with Chronic Heart Failure. Results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 2004; 109 (13): 1594-602. DOI: 10.1161/01.CIR.0000124490.27666.B2.</mixed-citation><mixed-citation xml:lang="en">Mann DL, McMurray J, Packer M, et al. Targeted Anticytokine Therapy in Patients with Chronic Heart Failure. Results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 2004; 109 (13): 1594-602. DOI: 10.1161/01.CIR.0000124490.27666.B2.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Sliwa K, Skudicky D, Candy G, et al. Randomised investigation of effects of pentoxifylline on left-ventricular performance in idiopathic dilated cardiomyopathy. Lancet. 1998; 351: 1091-3. DOI: 10.1093/eurjhf/hfn040.</mixed-citation><mixed-citation xml:lang="en">Sliwa K, Skudicky D, Candy G, et al. Randomised investigation of effects of pentoxifylline on left-ventricular performance in idiopathic dilated cardiomyopathy. Lancet. 1998; 351: 1091-3. DOI: 10.1093/eurjhf/hfn040.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Sliwa K, Woodiwiss A, Candy G, et al. Effects of pentoxifylline on cytokine profiles and left ventricular performance in patients with decompensated congestive heart failure secondary to idiopathic dilated cardiomyopathy. Am J Cardiol. 2002; 90: 1118-22.</mixed-citation><mixed-citation xml:lang="en">Sliwa K, Woodiwiss A, Candy G, et al. Effects of pentoxifylline on cytokine profiles and left ventricular performance in patients with decompensated congestive heart failure secondary to idiopathic dilated cardiomyopathy. Am J Cardiol. 2002; 90: 1118-22.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Sliwa K, Woodiwiss A, Kone VN, et al. Therapy of ischemic cardiomyopathy with the immunomodulating agent pentoxifylline: results of a randomized study. Circulation. 2004; 109: 750-5.</mixed-citation><mixed-citation xml:lang="en">Sliwa K, Woodiwiss A, Kone VN, et al. Therapy of ischemic cardiomyopathy with the immunomodulating agent pentoxifylline: results of a randomized study. Circulation. 2004; 109: 750-5.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Torre-Amione G, Anker SD, Bourge RC, et al. Results of a non-specific immunomodulation therapy in chronic heart failure (ACCLAIM trial): a placebo-controlled randomised trial. 2008; 371 (9608): 228-36. DOI: 10.1016/S0140-6736(08)60134-8.</mixed-citation><mixed-citation xml:lang="en">Torre-Amione G, Anker SD, Bourge RC, et al. Results of a non-specific immunomodulation therapy in chronic heart failure (ACCLAIM trial): a placebo-controlled randomised trial. 2008; 371 (9608): 228-36. DOI: 10.1016/S0140-6736(08)60134-8.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Simonsen S, Kjekshus J, Nitter-Hauge S, et al. Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure. Circulation. 2001; 103: 220-5.</mixed-citation><mixed-citation xml:lang="en">Simonsen S, Kjekshus J, Nitter-Hauge S, et al. Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure. Circulation. 2001; 103: 220-5.</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">McNamara DM, Holubkov R, Starling RC, et al. Controlled trial of intravenous immune globulin in recent-onset dilated cardiomyopathy. Circulation. 2001; 103: 2254-9.</mixed-citation><mixed-citation xml:lang="en">McNamara DM, Holubkov R, Starling RC, et al. Controlled trial of intravenous immune globulin in recent-onset dilated cardiomyopathy. Circulation. 2001; 103: 2254-9.</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Van Tassell BW, Buckley LF, Carbone S, et al. Interleukin-1 blockade in heart failure with preserved ejection fraction: rationale and design of the Diastolic Heart Failure Anakinra Response Trial 2 (D-HART2). Clin Cardiol. 2017 Sep; 40 (9): 626-32. DOI: 10.1002/clc.22719.</mixed-citation><mixed-citation xml:lang="en">Van Tassell BW, Buckley LF, Carbone S, et al. Interleukin-1 blockade in heart failure with preserved ejection fraction: rationale and design of the Diastolic Heart Failure Anakinra Response Trial 2 (D-HART2). Clin Cardiol. 2017 Sep; 40 (9): 626-32. DOI: 10.1002/clc.22719.</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Gullestad L, Ueland T, Fjeld JG, et al. Effect of thalidomide on cardiac remodeling in chronic heart failure: results of a double blind, placebo-controlled study. Circulation. 2005; 112: 3408-14. DOI: 10.1161/CIRCULATIONAHA.105.564971.</mixed-citation><mixed-citation xml:lang="en">Gullestad L, Ueland T, Fjeld JG, et al. Effect of thalidomide on cardiac remodeling in chronic heart failure: results of a double blind, placebo-controlled study. Circulation. 2005; 112: 3408-14. DOI: 10.1161/CIRCULATIONAHA.105.564971.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
